about
Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAPA mouse model uncovers LKB1 as an UVB-induced DNA damage sensor mediating CDKN1A (p21WAF1/CIP1) degradationGermline mutations in BAP1 predispose to melanocytic tumorsMutations in GNA11 in uveal melanomaFrequent somatic mutations of GNAQ in uveal melanoma and blue naeviRecurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapyDistinct sets of genetic alterations in melanomaThe state of melanoma: challenges and opportunitiesPhylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination.Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy.Improving melanoma classification by integrating genetic and morphologic featuresAbsence of somatic mutations of NEMO in keratoacanthomaSomatic mutation of epidermal growth factor receptor in a small subset of cutaneous squamous cell carcinoma.MC1R variants increase risk of melanomas harboring BRAF mutations.Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trialSporadic naturally occurring melanoma in dogs as a preclinical model for human melanomaGermline variation of the melanocortin-1 receptor does not explain shared risk for melanoma and thyroid cancer.Kinase fusions are frequent in Spitz tumours and spitzoid melanomas.Ambiguous melanocytic tumors with loss of 3p21.Loss-of-function fibroblast growth factor receptor-2 mutations in melanomaRegulatory network decoded from epigenomes of surface ectoderm-derived cell types.Clinical, histopathologic, and genomic features of Spitz tumors with ALK fusions.The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial.Frequent p16-independent inactivation of p14ARF in human melanoma.Activating MET kinase rearrangements in melanoma and Spitz tumours.Metastatic melanoma with striking adenocarcinomatous differentiation illustrating phenotypic plasticity in melanomaMolecular genetics of melanocytic neoplasia: practical applications for diagnosis.Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion.A distinct subset of atypical Spitz tumors is characterized by BRAF mutation and loss of BAP1 expression.CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing.The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin.Beta-catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development.Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathwayGenomic analysis of melanocytic neoplasia.GNAQ and GNA11 mutations in melanocytomas of the central nervous systemThe molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia.Clonal BRAF mutations in melanocytic nevi and initiating role of BRAF in melanocytic neoplasiaPhase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT InhibitionSOX10 ablation arrests cell cycle, induces senescence, and suppresses melanomagenesis
P50
Q24298571-9600A606-30E8-4072-8B37-E9DFE09635BCQ24306061-5860B500-54DE-4446-9C1E-5834512AD150Q24594891-3369C163-E271-4999-BF60-27AA5BD23863Q24625723-44029BDA-B245-415B-983B-ACE2C5320B38Q24646052-BAA4FB15-21A1-4378-B409-9154992FCC86Q27852482-FE55D68F-8FB8-4FA9-B0AB-8771A0569286Q29614965-DB31FAB3-17F9-4274-9448-4653340A5DD4Q30276971-214B250E-16AB-4C9A-AD11-00A26AB60137Q30403025-A76591F5-C786-477A-B01C-DDFD88E7194CQ33276475-4F38FC5D-50CF-4C57-AA0D-81F5BA0F0CCBQ33340639-C8DDF3DC-B938-47BB-83F9-2B2F333D465DQ33663859-03FB0BEA-BA52-4C81-BE3D-9F5D278FE8FBQ33671646-9C4346DE-92FD-47CC-89C1-E1E70CB82F1BQ33715143-5405AD30-7BF5-4B3E-80A5-1B179392E9D1Q33749057-317455DC-4757-46F0-B0D9-A6EB0D788A9DQ33790743-501CFEE9-1942-4A17-BDCE-899AA05B6FA0Q33822934-17C2A674-A0D7-4312-8A50-518C3D5C2094Q33854847-77B4D3B5-C4A9-4C72-8FCC-5AC564D604E8Q33911349-265E54F0-C3BF-4B52-997E-BD84EB9EC600Q34520671-E7ECBFF1-1F14-4EBC-BAAE-27A8110FD968Q35272189-54439AE1-A3A8-48FC-9230-68ABBA530002Q35433876-8624715C-CF34-4199-BF74-437F6B173D33Q35475284-214AFFF7-A168-4FDA-B897-8F3DD8ED81F7Q35541602-402CCA7B-FBE9-4693-9DA6-9C066EE3C290Q35658282-2ABA6888-446A-4332-B78E-AF42161F88E5Q35871461-5D4E408E-B39A-42C7-B526-CC7581646884Q35888628-8F6C77DD-60B6-4D7B-8043-7C7A06490A48Q35915107-8A6443A5-9FF3-454C-8FA8-4649DF3D8FF1Q35963400-FE155EE1-2DFC-4763-8E9B-6DCF974E6279Q35965678-64D13465-CE20-483B-A5A0-F86FB088B1FDQ35995950-B3485F6D-B297-49FA-AA42-3F61DAA6EDA3Q36092451-F0614AB1-55E6-44A5-914A-06B6B153A55BQ36103651-F4C0EBDF-947D-4BBC-8B40-76C4794193A8Q36109039-D3E6D599-2D29-4765-AFEF-19AF43C89070Q36340154-605CD7BE-2037-4122-A9F3-AFFEA7A46B47Q36391571-5E65E0FD-9987-4893-B80E-90561F92128FQ36798179-F7F1FB42-F034-4F91-BD31-40451CB250C8Q36942437-A512F703-A292-48A4-ADB9-774250EF2DA1Q37237619-3A47F49B-EA51-4218-A2C8-0ECFC12861ADQ37243181-C360F9DB-010C-4755-8686-20740958B9E3
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Boris C. Bastian
@ast
Boris C. Bastian
@en
Boris C. Bastian
@es
Boris C. Bastian
@sl
type
label
Boris C. Bastian
@ast
Boris C. Bastian
@en
Boris C. Bastian
@es
Boris C. Bastian
@sl
prefLabel
Boris C. Bastian
@ast
Boris C. Bastian
@en
Boris C. Bastian
@es
Boris C. Bastian
@sl
P106
P1153
7005685019
P21
P31
P496
0000-0003-1836-6062